Trial Profile
104317: An Open-Label Compassionate Use Access and Long-Term Access Study of Anti IL-5 (Mepolizumab) Treatment in Subjects With Hypereosinophilic Syndrome. 201956: A Long-term Access Programme for Subjects With Severe Asthma Who Participated in a GSK-sponsored Mepolizumab Clinical Study. 112562: Expanded Access to Mepolizumab for Patients With Hypereosinophilic Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary) ; Mepolizumab (Primary)
- Indications Asthma; Hypereosinophilic syndrome
- Focus Adverse reactions; Expanded access
- Sponsors Glaxo Research and Development Limited; GlaxoSmithKline; GSK
- 13 Sep 2023 Results (n=514) presented at the 33rd Annual Congress of the European Respiratory Society
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI173745).
- 23 Nov 2020 Status changed from recruiting to completed.